Nirmatrelvir-Ritonavir Fails to Reduce Hospitalization in Vaccinated Outpatients

Nirmatrelvir-ritonavir has served as a primary outpatient intervention for mild-to-moderate COVID-19, particularly for patients at high risk of disease progression [1, 2, 3]. Early clinical data and target trial emulations (a statistical method that uses observational data to simulate the design of a randomized controlled trial) established its efficacy in reducing hospitalization and mortality among unvaccinated individuals during the Delta variant wave [4, 5, 6]. Meta-analyses of these early data demonstrated significant reductions in all-cause mortality (Relative Risk 0.36; 95% Confidence Interval: 0.27 to 0.50) and intensive care unit admission (Relative Risk 0.45; 95% Confidence Interval: 0.27 to 0.73) [7]. However, as the viral landscape shifted toward Omicron subvariants and population immunity increased, the magnitude of this benefit has become less certain [8, 4]. While some studies suggest a protective effect in older or immunocompromised populations, others highlight that the absolute risk reduction in lower-risk or vaccinated groups may be negligible [9, 10]. A new multi-country analysis now provides critical data on whether this antiviral remains an effective tool for the modern, vaccinated patient.